Pneumonia during remission induction chemotherapy in patients with acute leukemia

Annals of the American Thoracic Society

Volumn 10, Issue 5, 2013, Pages 432-440

  Garcia, Javier Barreda ^a   Lei, Xiudong ^a   Wierda, William ^a   Cortes, Jorge E ^a   Dickey, Burton F ^a   Evans, Scott E ^a   Ost, David E ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Epidemiology; Fungal pneumonia; Leukemia; Opportunistic infections; Pneumonia

Indexed keywords

ACICLOVIR; ALBUMIN; ANTINEOPLASTIC AGENT; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; FLUCONAZOLE; LEVOFLOXACIN; METHOTREXATE; POSACONAZOLE; VALACICLOVIR; VINCRISTINE; VORICONAZOLE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER REGRESSION; CLINICAL FEATURE; COHORT ANALYSIS; DRUG MEGADOSE; FATALITY; FEMALE; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; INDUCTION CHEMOTHERAPY; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; NEUTROPHIL COUNT; OUTCOME ASSESSMENT; PNEUMONIA; PROPHYLAXIS; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; THROMBOCYTE COUNT;

ACUTE DISEASE; ADULT; AGE FACTORS; AGED; COHORT STUDIES; FEMALE; HUMANS; HYPOALBUMINEMIA; INDUCTION CHEMOTHERAPY; LEUKEMIA; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYELODYSPLASTIC SYNDROMES; NEUTROPENIA; OPPORTUNISTIC INFECTIONS; PNEUMONIA; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROPORTIONAL HAZARDS MODELS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; RISK FACTORS; THROMBOCYTOPENIA;

EID: 84892152191     PISSN: 23256621     EISSN: None     Source Type: Journal    
DOI: 10.1513/AnnalsATS.201304-097OC     Document Type: Article

References (32)

1. Appelbaum FR, Gundacker H, Head DR, Slovak ML, Willman CL, Godwin JE, Anderson JE, Petersdorf SH. Age and acute myeloid leukemia. Blood 2006;107:3481-3485.
2. Estey EH. Therapeutic options for acute myelogenous leukemia. Cancer 2001;92:1059-1073.
3. Ferrara F, Schiffer CA. Acute myeloid leukaemia in adults. Lancet 2013;381:484-495.
4. Lowenberg B, Ossenkoppele GJ, van Putten W, Schouten HC, Graux C, Ferrant A, Sonneveld P, Maertens J, Jongen-Lavrencic M, von Lilienfeld-Toal M, et al.; Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON); German AML Study Group (AMLSG); Swiss Group for Clinical Cancer Research (SAKK) Collaborative Group. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med 2009;361:1235-1248.
5. [Published erratum appears in N Engl J Med 362:1155
6. de Witte T, Suciu S, Verhoef G, Labar B, Archimbaud E, Aul C, Selleslag D, Ferrant A, Wijermans P, Mandelli F, et al. Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS. Blood 2001;98: 2326-2331.
7. Itzykson R, Thé pot S, Quesnel B, Dreyfus F, Beyne-Rauzy O, Turlure P, Vey N, Recher C, Dartigeas C, Legros L, et al.; Groupe Francophone des Myelodysplasies(GFM). Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood 2011; 117:403-411.
8. Huguet F, Leguay T, Raffoux E, Thomas X, Beldjord K, Delabesse E, Chevallier P, Buzyn A, Delannoy A, Chalandon Y, et al. Pediatricinspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. J Clin Oncol 2009;27:911-918.
9. [Published erratum appears in J Clin Oncol 27:2574
10. Sive JI, Buck G, Fielding A, Lazarus HM, Litzow MR, Luger S, Marks DI, McMillan A, Moorman AV, Richards SM, et al. Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII/ECOG2993 trial. Br J Haematol 2012; 157:463-471.
11. Cannas G, Pautas C, Raffoux E, Quesnel B, de Botton S, de Revel T, Reman O, Gardin C, Elhamri M, Boissel N, et al. Infectious complications in adult acute myeloid leukemia: analysis of the Acute Leukemia French Association-9802 prospective multicenter clinical trial. Leuk Lymphoma 2012;53:1068-1076.
12. Rossini F, Verga M, Pioltelli P, Giltri G, Sancassani V, Pogliani EM, Corneo G. Incidence and outcome of pneumonia in patients with acute leukemia receiving first induction therapy with anthracyclinecontaining regimens. Haematologica 2000;85:1255-1260.
13. Specchia G, Pastore D, Carluccio P, Mele G, Montagna MT, Liso A, Rizzi R, Ianora AS, Liso V. Pneumonia in acute leukemia patients during induction therapy: experience in a single institution. Leuk Lymphoma 2003;44:97-101.
14. Yoshida M, Akiyama N, Fujita H, Miura K, Miyatake J, Handa H, Kito K, Takahashi M, Shigeno K, Kanda Y, et al. Analysis of bacteremia/fungemia and pneumonia accompanying acute myelogenous leukemia from 1987 to 2001 in the Japan Adult Leukemia Study Group. Int J Hematol 2011;93:66-73.
15. Wilhelm M, Kantarjian HM, O'Brien S, Pierce S, Keating MJ, Freireich EJ, Estey EH. Pneumonia during remission induction chemotherapy in patients with AML or MDS. Leukemia 1996;10:1870-1873.
16. Chaoui D, Legrand O, Roche N, Cornet M, Lefebvre A, Peffault de Latour R, Sanhes L, Huchon G, Marie JP, Rabbat A. Incidence and prognostic value of respiratory events in acute leukemia. Leukemia 2004;18:670-675.
17. Offidani M, Corvatta L, Malerba L, Marconi M, Bichisecchi E, Cecchini S, Manso E, Principi T, Gasparini S, Leoni P. Risk assessment of patients with hematologic malignancies who develop fever accompanied by pulmonary infiltrates: a historical cohort study. Cancer 2004;101:567-577.
18. Clement CG, Evans SE, Evans CM, Hawke D, Kobayashi R, Reynolds PR, Moghaddam SJ, Scott BL, Melicoff E, Adachi R, et al. Stimulation of lung innate immunity protects against lethal pneumococcal pneumonia in mice. Am J Respir Crit Care Med 2008;177:1322-1330.
19. Tuvim MJ, Gilbert BE, Dickey BF, Evans SE. Synergistic TLR2/6 and TLR9 activation protects mice against lethal influenza pneumonia. PLoS ONE 2012;7:e30596.
20. Tuvim MJ, Evans SE, Clement CG, Dickey BF, Gilbert BE. Augmented lung inflammation protects against influenza A pneumonia. PLoS ONE 2009;4:e4176.
21. Evans SE, Tuvim MJ, Fox CJ, Sachdev N, Gibiansky L, Dickey BF. Inhaled innate immune ligands to prevent pneumonia. Br J Pharmacol 2011;163:195-206.
22. Duggan JM, You D, Cleaver JO, Larson DT, Garza RJ, Guzmá n Pruneda FA, Tuvim MJ, Zhang J, Dickey BF, Evans SE. Synergistic interactions of TLR2/6 and TLR9 induce a high level of resistance to lung infection in mice. J Immunol 2011;186:5916-5926.
23. Bodey GP, Powell RD Jr., Hersh EM, Yeterian A, Freireich EJ. Pulmonary complications of acute leukemia. Cancer 1966;19: 781-793.
24. Ewig S, Glasmacher A, Ulrich B, Wilhelm K, Schafer H, Nachtsheim KH. Pulmonary infiltrates in neutropenic patients with acute leukemia during chemotherapy: outcome and prognostic factors. Chest 1998;114:444-451.
25. American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-Acquired, ventilator-Associated, and healthcare-Associated pneumonia. Am J Respir Crit Care Med 2005;171:388-416.
26. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002; 34:1094-1097.
27. Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, Camporota L, Slutsky AS; ARDS Definition Task Force. Acute respiratory distress syndrome: the Berlin Definition. JAMA 2012; 307:2526-2533.
28. Estey E, Thall P, Andreeff M, Beran M, Kantarjian H, O'Brien S, Escudier S, Robertson LE, Koller C, Kornblau S, et al. Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J Clin Oncol 1994;12:671-678.
29. Estey E, Thall P, Beran M, Kantarjian H, Pierce S, Keating M. Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy. Blood 1997;90: 2969-2977.
30. Gray B. The cmprsk package. The Comprehensive R Archive Network. Vienna, Austria: Vienna University of Economics and Business Administration; 2007.
31. Al Ameri A, Koller C, Kantarjian H, Ravandi F, Verstovsek S, Borthakur G, Pierce S, Mattiuzzi G. Acute pulmonary failure during remission induction chemotherapy in adults with acute myeloid leukemia or high-risk myelodysplastic syndrome. Cancer 2010;116:93-97.
32. Li C, Li J, Li Y, Lang S, Yougbare I, Zhu G, Chen P, Ni H. Crosstalk between platelets and the immune system: old systems with new discoveries. Adv Hematol 2012;2012:384685.